Rhelion Life Sciences' subsidiary Filament Health Corp. participated in the FDA public hearing on September 14, 2026, discussing the potential future therapeutic use of psychedelic drugs. Filament's president, Sarit Hashkes, provided oral remarks highlighting their expertise and readiness to support regulated access pathways for psilocybin-based treatments like their patented drug candidate PEX010. The hearing aims to gather input on developing and evaluating psychedelic therapies, with Filament contributing to this important dialogue. This marks a significant step as the FDA explores regulatory frameworks for psychedelic medicines in the U.S.
Rhelion Life Sciences' subsidiary Filament Health's participation in the FDA hearing on psychedelic drug therapies is noted here with Pluang's Health sector market data as of Sep 14, 2026 18:52 WIB. Of 91 priced Health-sector US stocks tradable on Pluang, 50 rose and 28 fell today. Notable movers include Sanofi SA (SNY) at USD 43.50 with a 1-day change of +1.71%, Alcon AG (ALC) at USD 67.13 up +1.67%, and Inovio Pharmaceuticals Inc (INO) at USD 1.23 down -1.60%.
AirTripMaker has introduced a comprehensive Business Class Flight Routes Guide to help travelers from the US explore premium flight options to 15 major international destinations across Asia, Europe, Africa, and Australia. The guide covers airlines, ...
Interim results from the Phase 3 DASL-HiCaP trial show that adding darolutamide to standard androgen deprivation therapy (ADT) and radiation therapy reduces the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
Anthropic reported a massive increase in revenue, reaching $16.3 billion in the first half of 2026 compared to just $1.1 billion in the same period last year. This surge highlights rapid growth and strong demand for its products or services. The dram...
NEAR Protocol (NEAR) experienced the largest 24-hour decline among major cryptocurrencies, falling 8.93% to $4.47. Other notable drops included Bitcoin down 1.28% to $80,495, Ether down 1.38% to $2,360.57, and XRP down 3.45% to $1.28. These declines ...
Estimates of XRP's price rally during 2017-18 vary widely, from about 62,000% to 119,000%, depending on different starting prices and measurement periods. Vandell Aljarrah of Black Swan Capitalist highlighted a 630-fold rise when XRP moved above a tr...
